ERBB2 and neoplasm: A first-in‐human PET study with a GMP-grade HER2-targeting nanobody-based tracer for breast cancer has recently been completed at our university hospital [110] and new clinical trials with nanobodies targeting HER2 and tumor-associated macrophages are planned for 2016.